Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12
| Författare |
Martin Lagging Rune Wejstål A. S. Duberg S. Aleman O. Weiland Johan Westin |
|---|---|
| Publicerad i | Infectious Diseases |
| Volym | 50 |
| Nummer/häfte | 8 |
| Sidor | 569-583 |
| ISSN | 2374-4235 |
| Publiceringsår | 2018 |
| Publicerad vid |
Institutionen för biomedicin, avdelningen för infektionssjukdomar |
| Sidor | 569-583 |
| Språk | en |
| Länkar |
dx.doi.org/10.1080/23744235.2018.14... |
| Ämnesord | Hepatitis C virus, HCV, Guidelines, Direct-acting antiviral agents, Ribavirin, Genotype, People who inject drugs, PWIDs, Children, Chronic, kidney disease, HIV, Elimination, Eradication, Resistance associated, variants (RAVs), Resistance associated substitutions (RASs), genotype 1 infection, daclatasvir plus sofosbuvir, treatment-experienced, patients, treatment-naive patients, severe renal impairment, fixed-dose, combination, open-label, hcv infection, hepatocellular-carcinoma, phase-3 trial, Infectious Diseases |
| Ämneskategorier | Infektionsmedicin |
Aim: Following the approval of two new therapeutic combinations within the European Union in 2017, the former Swedish recommendations for the treatment of hepatitis C virus (HCV) infection from 2016 were deemed in need of updating. Materials and methods: An expert meeting to this end was held in Stockholm, Sweden in October 2017. Results and conclusions: An interferon-free combination of direct-acting antiviral agents is now recommended for all patients with chronic HCV infection, regardless of liver fibrosis stage, in order to limit morbidity and spread of the disease. An extended discussion of treatment for people who inject drugs in order to diminish transmission is included.
GÖTEBORGS UNIVERSITET • Box 100 • 405 30 Göteborg • Telefon: 031 786 0000
Kontakt • Organisationsnummer: 202100-3153 • Om webbplatsen
Facebook
Twitter
Instagram
Youtube